🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07335705
Recruiting Observational

Analysis of Factors Influencing the Quality of Bowel Preparation Before Colonoscopy in IBD Patients

NCT07335705 · tracked via the Priya Life Science China tracker
Sponsor
Changhai Hospital
Phase
Observational
Started
2025-12-08
Last updated
2026-05-14

Condition(s) studied

IBD (Inflammatory Bowel Disease)ColonoscopyColonoscopy: Bowel Preparation

Investigational drug(s) / intervention(s)

Standard Pre-colonoscopy Bowel Preparation Protocol

Standard Pre-colonoscopy Bowel Preparation Protocol: This involves standard clinical instructions including a low-residue diet prior to colonoscopy and the administration of bowel cleansing agents (e.g., Polyethylene Glycol) according to the split-dose regimen as per each participating center's routine practice. The timing, dosage, and specific agent used follow existing institutional guidelines.

Study summary

The primary objectives of this project are twofold. On the one hand, it aims to investigate the current status of bowel preparation protocols and their quality in IBD patients undergoing colonoscopy, particularly focusing on the implementation of these protocols across hospitals following the release of the 2023 bowel preparation guidelines. This will further standardize and optimize bowel preparation practices in China. On the other hand, the project seeks to identify and examine various risk factors contributing to poor bowel preparation quality in IBD patients, analyze their correlation with bowel preparation scores, and develop a risk prediction model for failed bowel preparation. This will provide a theoretical foundation for formulating personalized bowel preparation regimens tailored to individual patient conditions in the future.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients aged 18 years or older, of any gender, scheduled for colonoscopy; * Patients diagnosed with Inflammatory Bowel Disease (IBD) according to the 2023 edition of the Guidelines for the Diagnosis and Treatment of Inflammatory Bowel Disease; * Voluntary participation in this study and provision of signed informed consent. Exclusion Criteria: * History of acute myocardial infarction (within the past 6 months), severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders; * Current use of anticoagulants (e.g., aspirin, warfarin) or presence of coagulation disorders; * Pregnant or lactating women; * Acute intestinal infection within the past 2 weeks; * History of colorectal tumors, familial adenomatous polyposis, or Peutz-Jeghers syndrome; * History of intestinal obstruction, perforation, stenosis, or any other condition preventing completion of the examination; * Severe hearing impairment, cognitive dysfunction, or inability to cooperate with the survey; * Individuals already enrolled in this study who schedule a repeat colonoscopy; * Currently participating in another clinical observational trial or having participated in any other clinical trial within the past 60 days; * Refusal to sign the written informed consent form.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Changhai Hospital Shanghai Shanghai Municipality Recruiting

More Changhai Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07335705 on ClinicalTrials.gov ↗ ← All trials in China